Iron Mountain Inc vs Viatris Inc — how do they compare? Iron Mountain Inc trades at $114.8 (market cap $34.46B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Iron Mountain Inc is the larger of the two by market cap, and Iron Mountain Inc pays the higher dividend (2.99%). Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Viatris Inc for 57 Days on average.
| IRM | VTRS | |
|---|---|---|
Market Cap | $34.46B | $20.03B |
Volume | 1,379,608 | 14,109,977 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $18.27 |
52-Week Low | $78.86 | $9.74 |
Typical Hold Time | 80 Days | 57 Days |
Enterprise Value | $53.87B | $32.15B |
Dividend Yield | 2.99% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $114.51, down 1.05% on the day, with a bearish technical signal and elevated valuation metrics like a P/E of 82.09. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.60 surpassing the $0.543 forecast. The company is expanding its data center pipeline and digital solutions, targeting 300MW capacity, while revenue grew to $6.90 billion in 2025. However, net income margin has declined to 2.09%, and debt-to-asset ratio rose to 79.04% in 2025, indicating financial leverage concerns.
The outlook is mixed: strong analyst consensus with a $142.75 price target and 66.7% buy ratings support upside potential, but high debt, margin pressure, and bearish technicals pose risks. Growth in data centers and digital services offers opportunity, yet investors must weigh leverage and profitability trends against expansion prospects.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →